CU20200036A7 - Composiciones de vacuna estables que comprenden inter alia un flavivirus recombinante vivo atenuado y proceso para la preparación de las mismas - Google Patents
Composiciones de vacuna estables que comprenden inter alia un flavivirus recombinante vivo atenuado y proceso para la preparación de las mismasInfo
- Publication number
- CU20200036A7 CU20200036A7 CU2020000036A CU20200036A CU20200036A7 CU 20200036 A7 CU20200036 A7 CU 20200036A7 CU 2020000036 A CU2020000036 A CU 2020000036A CU 20200036 A CU20200036 A CU 20200036A CU 20200036 A7 CU20200036 A7 CU 20200036A7
- Authority
- CU
- Cuba
- Prior art keywords
- inter alia
- attenuated
- preparation
- same
- compositions including
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 230000002238 attenuated effect Effects 0.000 title abstract 3
- 241000710831 Flavivirus Species 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title 1
- 230000002163 immunogen Effects 0.000 abstract 3
- 241000700605 Viruses Species 0.000 abstract 2
- 241000710829 Dengue virus group Species 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 238000004108 freeze drying Methods 0.000 abstract 1
- 230000005847 immunogenicity Effects 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 239000003755 preservative agent Substances 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 230000035899 viability Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/18—Togaviridae; Flaviviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- C12N7/06—Inactivation or attenuation by chemical treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
<p>Composiciones inmunogénicas liofilizadas estables que comprenden, entre otros, flavivirus vivos atenuados recombinantes, más preferiblemente virus del dengue recombinantes vivos atenuados, al menos un hidrato de carbono, al menos un aminoácido, y que son particularmente susceptibles de tratamientos de liofilización rápida en donde, la composición conserva las características deseadas de un virus, que incluye la viabilidad, inmunogenicidad y estabilidad del virus. La mencionada composición inmunogénica está libre de conservantes, polímeros y surfactantes. Los métodos para fabricar las mencionadas composiciones inmunogénicas liofilizadas estables. </p>
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201721036696 | 2017-10-16 | ||
| PCT/IN2018/050645 WO2019077622A1 (en) | 2017-10-16 | 2018-10-10 | STABLE VACCINE COMPOSITIONS COMPRISING, BOTH, A LIVING RECOMBINANT FLAVIVUS ATTENUATED AND PROCESS FOR PREPARING THE SAME |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20200036A7 true CU20200036A7 (es) | 2021-03-11 |
| CU24701B1 CU24701B1 (es) | 2024-04-08 |
Family
ID=66173564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2020000036A CU24701B1 (es) | 2017-10-16 | 2018-10-10 | Composiciones de vacuna estables que comprenden inter alia un flavivirus recombinante vivo atenuado y proceso para la preparación de las mismas |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US11660333B2 (es) |
| EP (1) | EP3697897A4 (es) |
| JP (1) | JP7261239B2 (es) |
| KR (1) | KR102755215B1 (es) |
| CN (1) | CN111655844B (es) |
| AR (1) | AR114138A1 (es) |
| AU (1) | AU2018352447B2 (es) |
| CA (1) | CA3079151A1 (es) |
| CO (1) | CO2020006037A2 (es) |
| CR (1) | CR20200212A (es) |
| CU (1) | CU24701B1 (es) |
| EA (1) | EA202090967A1 (es) |
| GE (2) | GEP20237575B (es) |
| MX (1) | MX2020004085A (es) |
| MY (1) | MY209364A (es) |
| PE (1) | PE20210106A1 (es) |
| PH (1) | PH12020550266A1 (es) |
| PY (1) | PY1889910A (es) |
| SA (1) | SA520411768B1 (es) |
| SG (1) | SG11202003408TA (es) |
| TW (1) | TWI812650B (es) |
| UA (1) | UA127829C2 (es) |
| WO (1) | WO2019077622A1 (es) |
| ZA (1) | ZA202002852B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2903231C (en) | 2013-03-15 | 2025-12-09 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Compositions and methods for dengue virus chimeric constructs in vaccines |
| JP7042341B2 (ja) | 2017-12-07 | 2022-03-25 | メルク・シャープ・アンド・ドーム・コーポレーション | デングウイルスワクチン組成物の製剤 |
| US11426461B2 (en) | 2018-09-05 | 2022-08-30 | Takeda Vaccines, Inc. | Methods for preventing dengue and hepatitis A |
| EP4072582A4 (en) * | 2019-12-10 | 2023-05-24 | Repligen Corporation | PROCESS FOR PREPARING VIRAL VECTORS |
| AU2021217370A1 (en) * | 2020-02-04 | 2022-08-18 | Regeneron Pharmaceuticals, Inc. | Target residual moisture content for lyophilized drug product |
| GB2600468A (en) * | 2020-10-30 | 2022-05-04 | Excivion Ltd | Adjuvant composition |
| US12318439B2 (en) * | 2021-05-09 | 2025-06-03 | Board Of Regents, The University Of Texas System | Attenuating viral mutations in protein genes |
| US20250057939A1 (en) * | 2021-09-08 | 2025-02-20 | Serum Institute Of India Private Limited | Freeze-dried viral combination vaccine compositions and process for preparation thereof |
| WO2023158989A1 (en) * | 2022-02-15 | 2023-08-24 | Takeda Vaccines, Inc. | Dengue vaccine batch mixing process |
| JP2025535345A (ja) * | 2022-10-18 | 2025-10-24 | タケダ ワクチン，インコーポレイテッド | デング熱ワクチン製剤 |
| EP4626574A1 (en) * | 2022-11-29 | 2025-10-08 | Takeda Vaccines, Inc. | Large-scale flaviviral vaccine production and manufacture |
| WO2025027616A1 (en) * | 2023-08-01 | 2025-02-06 | Serum Institute Of India Private Limited | Freeze-dried viral vaccine compositions and method of manufacturing thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8444991B2 (en) * | 2007-03-22 | 2013-05-21 | The Regents Of The University Of Colorado, A Body Corporate | Method of preparing an immunologically-active adjuvant-bound dried vaccine composition |
| EP2143440A1 (fr) * | 2008-07-09 | 2010-01-13 | Sanofi Pasteur | Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués |
| CN102215865B (zh) * | 2008-09-24 | 2013-10-30 | 米迪缪尼有限公司 | 病毒纯化方法 |
| CN102202688B (zh) | 2008-11-07 | 2017-04-12 | 印度血清研究所私人有限公司 | 稳定、干燥的轮状病毒疫苗、其组合物和制备其的方法 |
| ES2630012T3 (es) * | 2010-12-02 | 2017-08-17 | Oncolytics Biotech Inc. | Formulaciones virales liofilizadas |
| US20150030565A1 (en) * | 2012-01-09 | 2015-01-29 | Sanofi Pasteur Biologics, Llc | Purification of flaviviruses |
| US10004795B2 (en) * | 2015-09-08 | 2018-06-26 | Fundacao Butantan | Process for preparing an attenuated tetravalent dengue vaccine |
| EP3355916A4 (en) | 2015-09-30 | 2018-08-29 | Panacea Biotec Limited | Stable live attenuated recombinant dengue vaccine |
| US10751408B2 (en) * | 2016-02-23 | 2020-08-25 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for making and using thermostable immunogenic formulations with increased compatibility of use as vaccines against one or more pathogens |
-
2018
- 2018-10-10 WO PCT/IN2018/050645 patent/WO2019077622A1/en not_active Ceased
- 2018-10-10 UA UAA202002972A patent/UA127829C2/uk unknown
- 2018-10-10 MX MX2020004085A patent/MX2020004085A/es unknown
- 2018-10-10 CN CN201880078804.XA patent/CN111655844B/zh active Active
- 2018-10-10 GE GEAP201815338A patent/GEP20237575B/en unknown
- 2018-10-10 SG SG11202003408TA patent/SG11202003408TA/en unknown
- 2018-10-10 CR CR20200212A patent/CR20200212A/es unknown
- 2018-10-10 MY MYPI2020001833A patent/MY209364A/en unknown
- 2018-10-10 EA EA202090967A patent/EA202090967A1/ru unknown
- 2018-10-10 JP JP2020542220A patent/JP7261239B2/ja active Active
- 2018-10-10 PE PE2020000644A patent/PE20210106A1/es unknown
- 2018-10-10 CA CA3079151A patent/CA3079151A1/en active Pending
- 2018-10-10 GE GEAP202315338A patent/GEAP202315338A/en unknown
- 2018-10-10 US US16/756,227 patent/US11660333B2/en active Active
- 2018-10-10 AU AU2018352447A patent/AU2018352447B2/en active Active
- 2018-10-10 KR KR1020207014037A patent/KR102755215B1/ko active Active
- 2018-10-10 EP EP18867836.1A patent/EP3697897A4/en active Pending
- 2018-10-10 CU CU2020000036A patent/CU24701B1/es unknown
- 2018-10-12 AR ARP180102954A patent/AR114138A1/es not_active Application Discontinuation
- 2018-10-12 TW TW107135951A patent/TWI812650B/zh active
- 2018-10-12 PY PY201801889910A patent/PY1889910A/es unknown
-
2020
- 2020-04-14 PH PH12020550266A patent/PH12020550266A1/en unknown
- 2020-04-14 SA SA520411768A patent/SA520411768B1/ar unknown
- 2020-05-15 CO CONC2020/0006037A patent/CO2020006037A2/es unknown
- 2020-05-15 ZA ZA2020/02852A patent/ZA202002852B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU20200036A7 (es) | Composiciones de vacuna estables que comprenden inter alia un flavivirus recombinante vivo atenuado y proceso para la preparación de las mismas | |
| BRPI0809663A8 (pt) | Composição de vírus vivo atenuado, usos da mesma, métodos de diminuição da inativação de vírus vivo atenuado, e kit para diminuir a inativação de uma composição de vírus vivo atenuado. | |
| MX2018009917A (es) | Vacuna contra el virus del zika. | |
| PE20150356A1 (es) | Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue | |
| GEP20237539B (en) | Formulations of dengue virus vaccine compositions | |
| AR113257A1 (es) | Virus chikungunya inmunogénico | |
| MX2018010958A (es) | Vacuna para virus de zika atenuado vivo. | |
| PE20140646A1 (es) | Vacuna de virus de dengue inactivado | |
| EA201390812A1 (ru) | Лиофилизированные вирусные составы | |
| ECSP18081582A (es) | Constructos de alfavirus vivo atenuado y métodos y usos de los mismos | |
| MX383330B (es) | Particula tipo virus de flavivirus. | |
| CU20180025A7 (es) | Proceso de preparación de una vacuna tetravalente atenuada contra el virus del dengue | |
| MX2023012530A (es) | Composición y metodos de vacuna adyuvada. | |
| ECSP20007842A (es) | Composiciones y métodos para formulaciones de alfavirus vivos atenuados | |
| AR103427A1 (es) | Vacuna contra la fiebre aftosa | |
| BR112015031226A2 (pt) | Composição de vacina, e, uso da composição de vacina | |
| MX2021013728A (es) | Ibv atenuado con tropismo de cultivo celular y tisular extendido. | |
| UY35418A (es) | Vacuna que proporciona protección frente a diferentes Picornavirus humanos. | |
| AR118881A1 (es) | Composiciones de virus inactivado y formulaciones de vacuna contra el zika | |
| CL2018001978A1 (es) | Inactivación de patógenos por delipidación | |
| MX2022010781A (es) | Vacuna contra el virus sars-cov-2 con adyuvante cpg. | |
| MX2022012447A (es) | Vacuna inactivada contra el virus sars-cov-2. | |
| CO2026001700A2 (es) | Composiciones de vacunas virales liofilizadas y método de fabricación de las mismas | |
| AR105134A1 (es) | Vacunas contra la influenza con coincidencia antigénica | |
| PE20091105A1 (es) | Vacuna |